SEBI Blocks Par Drugs' ₹95 Crore Sale to Protect Shareholders

Introduction: SEBI Upholds Order Against Par Drugs

The Securities and Exchange Board of India (SEBI) on March 25, 2026, issued a confirmatory order upholding its decision to halt the proposed slump sale of Par Drugs and Chemicals Ltd.'s core business. The transaction, intended to transfer the business to a promoter-related entity, has been under regulatory scrutiny since late 2025. SEBI's decision underscores its commitment to protecting the interests of public shareholders amid concerns over valuation, transparency, and corporate governance.

Details of the Proposed Transaction

Vadodara-based Par Drugs and Chemicals, an Active Pharmaceutical Ingredient (API) manufacturer, announced its plan to sell its primary business undertaking in December 2024. On February 14, 2025, the company signed a Business Transfer Agreement (BTA) with Phal-Jig Fine Chemicals Pvt Ltd (PJFCPL). The deal was structured as a slump sale valued at approximately ₹95 crore. A key point of contention is that the buyer, PJFCPL, is part of Par Drugs and Chemicals' promoter group, raising immediate concerns about a potential conflict of interest and the fairness of the transaction for minority shareholders.

SEBI's Intervention and Rationale

Following a complaint from shareholders, SEBI initiated an investigation. The complaint alleged that the slump sale was structured at an artificially low valuation to benefit the promoter group at the expense of public investors. Acting on these concerns, SEBI issued an ex-parte interim order in September 2025, restraining Par Drugs from proceeding with the sale. The regulator cited prima facie irregularities in the valuation methodology, shareholder communication, and the voting process related to the deal's approval. SEBI's whole-time member, Kamlesh Chandra Varshney, noted that allowing the transaction to proceed could cause "grave injustice to the public shareholders since the transaction would become irreversible upon execution."

Severe Market Reaction and Shareholder Impact

The announcement of the slump sale had a significant negative impact on the company's stock value. According to SEBI's order, the market capitalization of Par Drugs and Chemicals eroded by nearly 70% following the announcement. In the immediate aftermath, the stock price plunged by 36% within just two days, reflecting widespread investor concern over the deal's terms. This sharp decline highlighted the market's lack of confidence in the valuation and the potential detriment to non-promoter shareholders.

Key Regulatory Directives

To ensure a fair assessment, SEBI has issued several directives. The regulator has instructed the National Stock Exchange (NSE) to appoint an independent registered valuer to conduct a fresh valuation of the business undertaking. This re-examination must use recognized valuation standards to determine the true and fair value of the assets being transferred. Following the valuation, the NSE is required to obtain a fairness opinion from a SEBI-registered merchant banker. Furthermore, Par Drugs, its management, and all signatories to the BTA have been ordered to cease and desist from any actions that could lead to the disposal of company assets until the investigation is complete and further directions are issued.

Timeline of Key Events

Analysis of the Corporate Governance Concerns

The core of the issue lies in the related-party nature of the transaction. When a company sells its primary assets to an entity controlled by its own promoters, the potential for undervaluation is high. Minority shareholders risk having the company's most valuable assets transferred away for a price that does not reflect their fair market value, thereby enriching the promoters while diminishing the value of the public-held entity. SEBI's intervention highlights the regulator's role in scrutinizing such deals to prevent the erosion of public shareholder wealth and uphold corporate governance standards.

Conclusion and Path Forward

SEBI's firm stance in the Par Drugs and Chemicals case serves as a clear message on the importance of transparency and fairness in related-party transactions. The confirmatory order ensures that the slump sale remains on hold pending a thorough and independent re-valuation of the business. The future of the deal now hinges on the findings of the independent valuer and the subsequent fairness opinion. Par Drugs and Chemicals has been given 21 days to respond to the order, but for now, the interests of public shareholders have been placed at the forefront, with regulatory oversight ensuring that any potential sale is conducted at a fair and justifiable price.